4.1 Article

Characteristics and survival of adult Swedish PAH and CTEPH patients 2000-2014

期刊

SCANDINAVIAN CARDIOVASCULAR JOURNAL
卷 50, 期 4, 页码 243-250

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/14017431.2016.1185532

关键词

Incident; prevalent; pulmonary hypertension; survival

资金

  1. Actelion Pharmaceuticals Sweden AB
  2. Bayer Health Care
  3. Eli Lilly Sweden
  4. Glaxo-SmithKline
  5. Nordicinfu Care
  6. Pfizer
  7. SALAR (SKL)
  8. ALF foundations

向作者/读者索取更多资源

Objectives: The Swedish Pulmonary Arterial Hypertension Register (SPAHR) is an open continuous register, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients from 2000 and onwards. We hereby launch the first data from SPAHR, defining baseline characteristics and survival of Swedish PAH and CTEPH patients.Design: Incident PAH and CTEPH patients 2008-2014 from all seven Swedish PAH-centres were specifically reviewed.Results: There were 457 PAH (median age: 67 years, 64% female) and 183 CTEPH (median age: 70 years, 50% female) patients, whereof 77 and 81%, respectively, were in functional class III-IV at diagnosis. Systemic hypertension, diabetes, ischaemic heart disease and atrial fibrillation were common comorbidities, particularly in those >65 years. One-, 3- and 5-year survival was 85%, 71% and 59% for PAH patients. Corresponding numbers for CTEPH patients with versus without pulmonary endarterectomy were 96%, 89% and 86% versus 91%, 75% and 69%, respectively. In 2014, the incidence of IPAH/HPAH, associated PAH and CTEPH was 5, 3 and 2 per million inhabitants and year, and the prevalence was 25, 24 and 19 per million inhabitants.Conclusion: The majority of the PAH and CTEPH patients were diagnosed at age >65 years, in functional class III-IV, and exhibiting several comorbidities. PAH survival in SPAHR was similar to other registers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据